Marshall Wace, LLP Monopar Therapeutics Transaction History

Marshall Wace, LLP

  • $78.4 Billion
  • Q4 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021
SELL
$5.05 - $6.49 $240,647 - $309,267
-47,653 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$5.76 - $10.6 $274,481 - $505,121
47,653 New
47,653 $295,000

About Monopar Therapeutics

MNPR Quotes by TradingView
  • Ticker MNPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,725,800
  • Market Cap $362M
  • Description
  • Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...
More about MNPR
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email